<p>CanSino Biologics Inc. said surging coronavirus infections around the world will allow it to quickly reach an interim milestone to analyze the efficacy of its single-shot vaccine.</p>.<p>The Chinese company is testing its vaccine in Pakistan, Mexico, Argentina, Chile and Russia, Zhu Tao, the company’s chief scientific officer, said at a forum in Zhuhai. CanSino needs 50 Covid-19 cases for interim analysis and expects to quickly get them, he said.</p>.<p><strong>Also read — <a href="https://www.deccanherald.com/international/cansino-biologics-delivers-covid-19-vaccine-to-mexico-for-late-stage-trial-911011.html" target="_blank">CanSino Biologics delivers Covid-19 vaccine to Mexico for late-stage trial</a></strong></p>.<p>CanSino is developing a shot using a cold-causing adenovirus as a vector, a similar type of vaccine as some others. Pre-existing immunity to the adenovirus vector won’t have a major impact on the vaccine’s ability to generate immune responses to the coronavirus, Zhu said.</p>.<p>Zhu said breakthroughs by Moderna Inc. and Pfizer Inc. have been encouraging and suggest experimental vaccines stand a better chance of clinical success.</p>.<p>China’s military has approved CanSino’s shot for use among its personnel.</p>
<p>CanSino Biologics Inc. said surging coronavirus infections around the world will allow it to quickly reach an interim milestone to analyze the efficacy of its single-shot vaccine.</p>.<p>The Chinese company is testing its vaccine in Pakistan, Mexico, Argentina, Chile and Russia, Zhu Tao, the company’s chief scientific officer, said at a forum in Zhuhai. CanSino needs 50 Covid-19 cases for interim analysis and expects to quickly get them, he said.</p>.<p><strong>Also read — <a href="https://www.deccanherald.com/international/cansino-biologics-delivers-covid-19-vaccine-to-mexico-for-late-stage-trial-911011.html" target="_blank">CanSino Biologics delivers Covid-19 vaccine to Mexico for late-stage trial</a></strong></p>.<p>CanSino is developing a shot using a cold-causing adenovirus as a vector, a similar type of vaccine as some others. Pre-existing immunity to the adenovirus vector won’t have a major impact on the vaccine’s ability to generate immune responses to the coronavirus, Zhu said.</p>.<p>Zhu said breakthroughs by Moderna Inc. and Pfizer Inc. have been encouraging and suggest experimental vaccines stand a better chance of clinical success.</p>.<p>China’s military has approved CanSino’s shot for use among its personnel.</p>